Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7738572 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CTSLCTSBCTSK | |
| SCHEMBL7741214 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CTSLCTSBCTSK | |
| SCHEMBL7739610 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CTSLCTSBCTSK | |
| SCHEMBL7738673 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CTSLCTSBCTSK | |
| SCHEMBL7741403 | 0.97 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CTSLCTSBCTSK | |
| SCHEMBL11930045 | 0.92 | ALDH1A1 (0.46) | ALDH1A1CYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL16109561 | 0.87 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL685573 | 0.87 | — | — | |
| SCHEMBL19734476 | 0.79 | CYP1A2 (0.41) | ALDH1A1CYP1A2CTSLCTSBCTSK | |
| SCHEMBL12085963 | 0.79 | ALDH1A1 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-6410748-B1 | Alicycli c group-containing monomer | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6291129-B1 | LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | ALDH1A1 4021/4885CYP1A2 4779/4885CTSL 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.